OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Insmed's Cash Flow from Operations for the
three
months ended in Mar. 2026 was MXN-4,017 Mil. Insmed's Revenue for the
three
months ended in Mar. 2026 was MXN5,517 Mil. Therefore, Insmed's OCF Margin % for the quarter that ended in Mar. 2026 was -72.80%.
The historical rank and industry rank for Insmed's OCF Margin % or its related term are showing as below:
MEX:INSM'
s OCF Margin % Range Over the Past 10 Years
Min: -2623.05 Med: -179.69 Max: -133.41
Current: -110.25
During the past 13 years, the highest OCF Margin % of Insmed was -133.41%. The lowest was -2623.05%. And the median was -179.69%.
MEX:INSM's OCF Margin % is ranked worse than 54.99% of 951
companies
in the Biotechnology industry
Industry Median: -64.23
vs MEX:INSM: -110.25
Insmed OCF Margin % Related Terms
Insmed OCF Margin % Historical Data
* Premium members only.
The historical data trend for Insmed's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INSM vs INCY, BNTX, ROIV: OCF Margin % Comparison
For the Biotechnology subindustry, Insmed's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Insmed's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (MEX:INSM) has a OCF Margin % of -72.80% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Insmed and its competitors. According to the industry distribution chart, Insmed ranks #523 out of 951 companies in the Biotechnology industry, placing it in the top 55%.
Is Insmed's OCF Margin % too high?
Insmed's current OCF Margin % is -72.80%. Based on the distribution chart, Insmed ranks #523 out of 951 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Insmed's OCF Margin % compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #523 out of 951 companies for OCF Margin %. This places Insmed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Insmed and its competitors. Insmed's current OCF Margin % is -72.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Insmed (MEX:INSM) has a current OCF Margin % of -72.80%. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current OCF Margin % is -72.80%. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Insmed (MEX:INSM), the current OCF Margin % is -72.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.
Key valuation signals for MEX:INSM:
OCF Margin %: -72.80%
GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score
Get the complete analysis for MEX:INSM
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
